She describes the unmet need for patients who no longer respond to the large CDK4/6 class of medicines, and the decades of work she has put into solving the problem of adding CDK2 inhibition into the equation.

She describes the work the company is doing, which has a lead program targeting PIP4K2C and is scheduled to be in the clinic later this year.

Interviewed by Sisterhood editorial board member Sheila Gujrathi, Kiran Mazumdar-Shaw describes her beginnings in designing enzymes, and eventually pioneering biologics and biosimilars after an initial success in making recombinant human insulin for the India market. She discusses her emphasis on affordable innovation and shares business learnings from her career.

Interviewed by Xilio Therapeutics President & CEO René Russo, Dr. Liebisch describes her start in the industry as a patent attorney, discusses why having a champion in a larger partner is key, and explains why she even once threw a party when Vigil discontinued a candidate. Vigil Neuroscience was acquired by Sanofi earlier this year for an equity value representing approximately $470 million, plus a CVR.

Interviewed by Sisterhood editorial board member Erika Smith, Jennifer Good describes the factors that have led to Trevi's success in an otherwise difficult biotech market. She highlights the importance of speaking clearly and honestly with investors and the company's board. Plus, Erika and Jennifer reflect on Life-Science SPRINTS, an internship program they stood up in the New Haven, Connecticut area.

Interviewed by Sisterhood editorial board member Daphne Zohar, Sophie Kornowski shares her keys to creating great assets, commercialization, partnerships, and, ultimately, executing a successful deal if the right opportunity comes along. Plus, her thoughts on leadership, mentorship, and being a successful CEO.

Interviewed by Sisterhood editorial board member Grace Colón, she describes the unmet need for developing evidence based products for women's heath, and women's sexual health specifically. Plus, how Daré has thought outside the box regarding its path to market, including utilizing compounding, her experience running a public company, thoughts on mitigating potential FDA delays, and advice for entrepreneurs.

Interviewed by Sisterhood editorial board member Julia Owens, Catherine Owen Adams shares her career journey, and discusses the perceived and real differences between pharma and biotech. She introduces us to Acadia Pharmaceuticals and talks about what it has been like in the job so far.

Interviewed by Sisterhood editorial board member Erika Smith, Paula Ragan shares her career path and things she has learned along the way. She describes what it is like managing a company during these volatile times for the sector, and previews a big readout X4 will have next year.

Interviewed by Normunity CEO Rachel Humphrey at MassBio's 2025 State of Possible Conference, Luba explains how the Sisterhood arms members with important information, she shares the impression of the Massachusetts ecosystem she has gained as a MassBio board member, and also describes the effort against cancer at Gallop that motivates her each day.